Eye drop showdown: which cyclosporine works best for dry eyes?
NCT ID NCT07368595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two approved cyclosporine eye drops—Vevye (0.1%) and a generic (0.05%)—in 60 adults with dry eye disease. Over 8 weeks, researchers will measure changes in goblet cells, which produce mucus to keep eyes moist. Participants use drops daily and visit the clinic every two weeks for exams.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclosporine eye drops (Vevye 0.1% and generic 0.05%)
- What this could lead to
- If successful, this could show which cyclosporine formulation better restores mucus-producing cells in the eye, potentially improving dry eye treatment.
- What could go wrong
- This is a small, early-phase trial (60 people) comparing two already-approved drugs, so it won't produce a new treatment. Results may not apply to all dry eye patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can acne drug harm the eyes? new study investigates
- Which eye drop wins the dry eye battle? a Head-to-Head test
- Can a new eye drop soothe dry eye? a trial puts TRYPTYR to the test
- New eye drop aims to soothe dryness after cataract surgery
- Can simple eye drops soothe dry eyes? new study puts OTC brands to the test
- New eye drop hopes to soothe dry eye sufferers